Background: Localization of nonpalpable breast lesions for breast-conserving surgery (BCS) remains highly variable and includes needle/wire localization (NL), radioactive seed localization, radar localization, and hematoma-directed ultrasound-guided (HUG) lumpectomy. The superiority of HUG lumpectomy over NL has been demonstrated repeatedly in terms of safety, accuracy, low positive margin rates, cosmesis, and patient satisfaction. In this study, we evaluate the cost effectiveness of HUG lumpectomy over NL for nonpalpable breast lesions.
Methods: We performed a retrospective review of 569 patients who underwent lumpectomy at the University of Arkansas for Medical Sciences from May 2014 through December 2017. Lumpectomies were stratified by localization technique, i.e. NL versus HUG. A cost-savings estimate was determined for the HUG localization technique, and a total amount of dollars saved over the study period was calculated.
Results: Overall, 569 lumpectomies were performed: 501 (88.0%) via HUG and 68 (12.0%) via NL. Intraoperative ultrasound was used in 566 operations (99.5%). Of the lumpectomies performed by HUG, 190 lesions (33.4%) were visible only on mammogram or breast magnetic resonance imaging prior to diagnostic core needle biopsy (CNB). Cost estimates comparing HUG with NL demonstrated a cost savings of $497.00 per procedure, the cost of preoperative needle localization by a radiologist, and a total of $94,430.00 for the study period.
Conclusion: In utilizing HUG lumpectomy, the initial CNB serves as the diagnostic and localization procedure, thus saving time and a painful second procedure on the day of operation. HUG lumpectomy is safe, accurate, reduces healthcare costs, and results in a better patient experience for the surgical removal of nonpalpable breast lesions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-018-6596-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery.
Breast Cancer Res Treat
January 2020
Department of Gynecology and Obstetrics, Heidelberg University, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
Purpose: To explore the ability of intraoperative specimen radiography (SR) to correctly identify positive margins in patients receiving breast conserving surgery (BCS). To assess whether the reoperation rate can be reduced by using this method.
Methods: This retrospective study included 470 consecutive cases receiving BCS due to a primarily diagnosed breast cancer.
Changes of breast and axillary surgery patterns in patients with primary breast cancer during the past decade.
Arch Gynecol Obstet
April 2019
Department of Gynecology and Obstetrics, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
Purpose: Breast-conserving therapy (BCT) is the standard procedure for most patients with primary breast cancer (BC). By contrast, axillary management is still under transition to find the right balance between avoiding of morbidity, maintaining oncological safety, and performing a staging procedure. The rising rate of primary systemic therapy creates further challenges for surgical management.
View Article and Find Full Text PDFCutting Healthcare Costs with Hematoma-Directed Ultrasound-Guided Breast Lumpectomy.
Ann Surg Oncol
October 2018
Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Background: Localization of nonpalpable breast lesions for breast-conserving surgery (BCS) remains highly variable and includes needle/wire localization (NL), radioactive seed localization, radar localization, and hematoma-directed ultrasound-guided (HUG) lumpectomy. The superiority of HUG lumpectomy over NL has been demonstrated repeatedly in terms of safety, accuracy, low positive margin rates, cosmesis, and patient satisfaction. In this study, we evaluate the cost effectiveness of HUG lumpectomy over NL for nonpalpable breast lesions.
View Article and Find Full Text PDFDevelopment and psychometric validation of a shorter version of the Breast Cancer Treatment Outcome Scale (BCTOS-12).
Breast
April 2018
Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany. Electronic address:
Objectives: Aesthetic and functional outcomes after oncoplastic breast-conserving surgery (BCS) are directly related to the patients' quality of life (QoL). The Breast Cancer Treatment Outcome Scale (BCTOS) is a validated but burdensome questionnaire for the assessment of these outcomes. The aim of the study was to strengthen and focus the BCTOS instrument by reducing the number of items and subscales without loss of information and validity.
View Article and Find Full Text PDFEarly toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer.
Int J Radiat Oncol Biol Phys
June 2015
Memorial Sloan-Kettering Cancer Center, New York, New York; Procure Proton Therapy Center, Somerset, New Jersey. Electronic address:
Purpose: To report dosimetry and early toxicity data in breast cancer patients treated with postoperative proton radiation therapy.
Methods And Materials: From March 2013 to April 2014, 30 patients with nonmetastatic breast cancer and no history of prior radiation were treated with proton therapy at a single proton center. Patient characteristics and dosimetry were obtained through chart review.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!